Seeking men and women aged 18 and older who have been diagnosed with intermediate, high, or very high risk myelodysplastic Syndrome for a study of an investigational drug added to standard treatment.
Participants in this study will have about 40 office visits over about 4 years. All participants will receive the investigational drug in combination with standard treatment for myelodysplastic syndrome (MDS) provided in 28-day cycles.
What we're hoping for
We are studying whether adding an investigational drug to the standard treatment is safe and effective for people who have been diagnosed with intermediate, high, or very high risk myelodysplastic syndrome (MDS).
ClinicalTrials.gov Identifier: NCT04878432